Cutting edge: Restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix

Journal of Immunology

Volumn 166, Issue 2, 2001, Pages 731-735

  Siemens, D R ^a   Elzey, B D ^a   Lubaroff, D M ^a   Bohlken, C ^a   Jensen, R J ^a   Swanson, A K ^a   Ratliff, T L ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; INSULIN; OVALBUMIN; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; VIRUS VECTOR;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; EMBRYO; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TRANSGENIC MOUSE; VIRUS IMMUNITY; VIRUS RECOMBINANT;

EID: 0035863883     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.2.731     Document Type: Article

References (43)

1. Tumor antigens recognized by T lymphocytes
2. Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cells surface antigens
3. Defining the molecular recognition of GLOBO H (human breast cancer) antigen through probe structures prepared by total synthesis
4. Expression of prostate-specific membrane antigen
5. Differential apomucin expression in normal and neoplastic tissues
6. Tumor antigens: A new look for the 1990s
7. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigans
8. Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T cell responses
9. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus
10. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine
11. Antigen-specific tumor vaccines: Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer
12. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses
13. Inhibitory effects of human sera on adenovirus-mediated gene transfer into rat liver
14. The murine cellular immune respouse to adenovirus type 5
15. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector
16. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses
17. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL
18. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens
19. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors
20. Inhibition of tumor necrosis factor α decreases inflammation and prolongs adenovirus gene expression in lung and liver
21. Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig
22. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung
23. Systemic delivery of insulin via an enhancer-free ocular device
24. Effects of basic fibroblast growth factor on in vivo cerebral tumorigenesis in rats
25. Regulation of local host-mediate anti-tumor mechanisms by cytokines: Direct and indirect effects on leukocyte recruitment and angiogenesis
26. Viral vector delivery in solid-state vehicles: Gene expression in a marine prostate cancer model
27. Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer
28. A human β-actin expression vector system directs high-level accumulation of antisense transcripts
29. + T cells induced by cross-presentation of self-antigens involves signaling through CD95 (Fas, Apo-1)
30. Altered vascular function after adenovirus-mediated overexpression of endothelial nitric oxide synthase
31. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver
32. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen
33. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose
34. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor
35. Immunity to methylcholanthrene induced sarcomas
36. Human tumor antigens are ready to fly
37. Targeting antigen into the phagocytic pathway in vivo induces protective tumor immunity
38. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity
39. Preclinical pharmacokinetics, manufacturing and safety studies supporting a multicenter cancer gene therapy trial
40. An autologous oral DNA vaccine protects against murine melanoma
41. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb
42. Constitutive class-I-restricted exogenous presentation of self antigens in vivo
43. The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice